Cypher In-Stent Restenosis Treatment Safety Upheld By J&J Investigators
This article was originally published in The Gray Sheet
Executive Summary
Eight-month follow-up of Johnson & Johnson/Cordis' 41-patient study evaluating the Cypher sirolimus-eluting stent for treating in-stent restenosis suggests the procedure is safe and effective, investigators reported March 19 at the American College of Cardiology annual scientific sessions in Atlanta
You may also be interested in...
Anti-Restenosis Alternative Envisioned By Biodegradable Stent Developers
Biodegradable stent R&D will accelerate as long-term efficacy data on drug-eluting stents becomes available, several presenters predicted at the Cardiovascular Revascularization Therapy conference in Washington, D.C. Jan. 26-29
Anti-Restenosis Alternative Envisioned By Biodegradable Stent Developers
Biodegradable stent R&D will accelerate as long-term efficacy data on drug-eluting stents becomes available, several presenters predicted at the Cardiovascular Revascularization Therapy conference in Washington, D.C. Jan. 26-29
Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents
Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents